N-cyclobutyl-4-methyl-1,3-thiazol-2-amine | 1250893-17-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-cyclobutyl-4-methyl-1,3-thiazol-2-amine
• CAS: 1250893-17-4
• 化学式: C₈H₁₂N₂S
• 分子量: 168.263
• InChiKey: TZYCIEBPQGELAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-cyclobutyl-4-methyl-1,3-thiazol-2-amine 在 caesium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 18.5h， 生成 N-cyclobutyl-N-(4-methyl-1,3-thiazol-2-yl)-2-(6-phenylpyridazin-3-yl)sulfanylacetamide
  参考文献：
  名称：

  Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: Development of a highly selective and more potent in vitro probe

  摘要：

  Further chemical optimization of the MLSCN/MLPCN probe ML077 (KCC2 IC50 = 537 nM) proved to be challenging as the effort was characterized by steep SAR. However, a multi-dimensional iterative parallel synthesis approach proved productive. Herein we report the discovery and SAR of an improved novel antagonist (VU0463271) of the neuronal-specific potassium-chloride cotransporter 2 (KCC2), with an IC50 of 61 nM and > 100-fold selectivity versus the closely related Na-K-2Cl cotransporter 1 (NKCC1) and no activity in a larger panel of GPCRs, ion channels and transporters. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.126

文献信息

• PROCESS FOR PREPARING MACROCYCLIC COMPOUNDS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP1863833B1

  公开（公告）日：2013-09-18
• [EN] PHARMACEUTICAL COMPOSITIONS FOR HEPATITIS C VIRAL PROTEASE INHIBITORS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES POUR INHIBITEURS DE PROTEASE VIRALE DE L'HEPATITE C
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2003066103A1

  公开（公告）日：2003-08-14

  Disclosed are pharmaceutical compositions of hepatitis C viral protease inhibitors having improved bioavailability, and methods of using these compositions for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. These compositions include co-solvent systems, lipid based systems, solid dispersions and granulations, and all comprise the hepatitis C viral protease inhibitor, at least one pharmaceutically acceptable amine and optionally one or more additional ingredients.
• [EN] PHARMACEUTICAL COMPOSITIONS COMPRISING HEPATITIS C VIRAL PROTEASE INHIBITORS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES INHIBITEURS DE PROTEASE DU VIRUS DE L'HEPATITE C
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2004009121A1

  公开（公告）日：2004-01-29

  Disclosed are pharmaceutical compositions of hepatitis C viral protease inhibitors having improved bioavailability, and methods of using these compositions for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. These compositions include co-solvent systems, lipid based systems, solid dispersions and granulations, and all comprise the hepatitis C viral protease inhibitor, at least one pharmaceutically acceptable amine and optionally one or more additional ingredients.